Biocon Generics Inc (BGI), a wholly owned subsidiary of Biocon, has inaugurated its first US manufacturing facility in Cranbury, New Jersey.   

Since Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma in 2023, the company has invested over USD 30 million to establish a state-of-the-art plant with an annual production capacity of 2 billion tablets. A few products have already been commercialised from the site, with several more in the pipeline.

This investment is part of Biocon’s broader strategy to diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint.

According to the company, its Cranbury facility represents a strategic advancement for its US operations, enabling faster access to essential therapies, enhanced supply reliability and a stronger connection with partners and healthcare providers, ultimately benefitting patients across the United States.

New Jersey Governor Phil Murphy graced the inauguration of the facility as the guest of honour, joined by Biocon Group Chairperson Kiran Mazumdar-Shaw, along with a distinguished gathering of dignitaries, customers, partners, and industry leaders.

“We are incredibly grateful that Biocon has decided to open its first US manufacturing facility in the Garden State. For years, Biocon has provided high-quality medicines and treatments to millions of patients across the globe. This state-of-the-art facility marks a significant moment in Biocon’s global expansion and reinforces New Jersey’s reputation as the medicine chest to the world,” said Governor Murphy.

Mazumdar-Shaw noted that Biocon’s first US FDA approved formulations facility in New Jersey marks a new chapter in its journey of global expansion.

“More than a milestone, it is a reaffirmation of our purpose to serve patients wherever they are. Governor Phil Murphy’s presence at the inauguration highlights the importance of Biocon’s role in fostering innovation, creating job opportunities, and strengthening the US healthcare ecosystem. This facility reflects our long-term commitment to deeper engagement with healthcare providers, innovators, and communities to build a healthier and equitable future,” she said.

Siddharth Mittal, CEO and Managing Director, Biocon, reiterated the company’s commitment to broadening global access to affordable therapies.

“This strategic investment brings us closer to patients, healthcare providers, and partners in this important market. The proximity allows us to deliver our vertically integrated, high-quality medicines more efficiently to patients across the United States and other markets, ensuring supply chain resilience and enabling us to advance our mission of expanding access to affordable therapies worldwide,” he stated.